688 related articles for article (PubMed ID: 23388123)
1. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification.
Akiba J; Nakashima O; Hattori S; Tanikawa K; Takenaka M; Nakayama M; Kondo R; Nomura Y; Koura K; Ueda K; Sanada S; Naito Y; Yamaguchi R; Yano H
Am J Surg Pathol; 2013 Apr; 37(4):496-505. PubMed ID: 23388123
[TBL] [Abstract][Full Text] [Related]
2. α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression.
Ikeda H; Sato Y; Yoneda N; Harada K; Sasaki M; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Hum Pathol; 2012 Nov; 43(11):1955-63. PubMed ID: 22516245
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers.
Ikeda H; Harada K; Sato Y; Sasaki M; Yoneda N; Kitamura S; Sudo Y; Ooi A; Nakanuma Y
Am J Clin Pathol; 2013 Sep; 140(3):329-40. PubMed ID: 23955451
[TBL] [Abstract][Full Text] [Related]
4. [Combined hepatocellular-cholangiocarcinoma (cholangiolocellular type) with stem-cell features: a clinicopathologic analysis of 26 cases].
Xu J; Zhang C; Qiao A; Xi Y
Zhonghua Bing Li Xue Za Zhi; 2016 Mar; 45(3):175-9. PubMed ID: 26956962
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic Characteristics of Hepatocellular Carcinoma With Reactive Ductule-like Components, a Subset of Liver Cancer Currently Classified as Combined Hepatocellular-Cholangiocarcinoma With Stem-Cell Features, Typical Subtype.
Shibahara J; Hayashi A; Misumi K; Sakamoto Y; Arita J; Hasegawa K; Kokudo N; Fukayama M
Am J Surg Pathol; 2016 May; 40(5):608-16. PubMed ID: 26735856
[TBL] [Abstract][Full Text] [Related]
6. Combined hepatocellular-cholangiocarcinoma with stem cell features, ductal plate malformation subtype: a case report and proposal of a new subtype.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):737-48. PubMed ID: 23573322
[TBL] [Abstract][Full Text] [Related]
7. Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence.
Zhang F; Chen XP; Zhang W; Dong HH; Xiang S; Zhang WG; Zhang BX
Histopathology; 2008 Jan; 52(2):224-32. PubMed ID: 18184271
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical and molecular features of cholangiolocellular carcinoma are similar to well-differentiated intrahepatic cholangiocarcinoma.
Balitzer D; Joseph NM; Ferrell L; Shafizadeh N; Jain D; Zhang X; Yeh M; di Tommaso L; Kakar S
Mod Pathol; 2019 Oct; 32(10):1486-1494. PubMed ID: 31186529
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
10. A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
Wakasa T; Wakasa K; Shutou T; Hai S; Kubo S; Hirohashi K; Umeshita K; Monden M
Hepatogastroenterology; 2007 Mar; 54(74):508-13. PubMed ID: 17523309
[TBL] [Abstract][Full Text] [Related]
11. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
[TBL] [Abstract][Full Text] [Related]
12. Combined hepatocellular cholangiocarcinoma: Controversies to be addressed.
Wang AQ; Zheng YC; Du J; Zhu CP; Huang HC; Wang SS; Wu LC; Wan XS; Zhang HH; Miao RY; Sang XT; Zhao HT
World J Gastroenterol; 2016 May; 22(18):4459-65. PubMed ID: 27182157
[TBL] [Abstract][Full Text] [Related]
13. Intrahepatic cholangiocarcinoma: new insights in pathology.
Sempoux C; Jibara G; Ward SC; Fan C; Qin L; Roayaie S; Fiel MI; Schwartz M; Thung SN
Semin Liver Dis; 2011 Feb; 31(1):49-60. PubMed ID: 21344350
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.
Komuta M; Spee B; Vander Borght S; De Vos R; Verslype C; Aerts R; Yano H; Suzuki T; Matsuda M; Fujii H; Desmet VJ; Kojiro M; Roskams T
Hepatology; 2008 May; 47(5):1544-56. PubMed ID: 18393293
[TBL] [Abstract][Full Text] [Related]
15. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Kim KH; Lee SG; Park EH; Hwang S; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
Ann Surg Oncol; 2009 Mar; 16(3):623-9. PubMed ID: 19130133
[TBL] [Abstract][Full Text] [Related]
16. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma.
Patsenker E; Wilkens L; Banz V; Osterreicher CH; Weimann R; Eisele S; Keogh A; Stroka D; Zimmermann A; Stickel F
J Hepatol; 2010 Mar; 52(3):362-9. PubMed ID: 20137822
[TBL] [Abstract][Full Text] [Related]
17. Combined hepatocellular carcinoma and cholangiocarcinoma with components of mucinous carcinoma arising in a cirrhotic liver.
Morita D; Kagata Y; Ogata S; Tsuda H; Hatsuse K; Mochizuki H; Matsubara O
Pathol Int; 2006 Apr; 56(4):222-6. PubMed ID: 16634969
[TBL] [Abstract][Full Text] [Related]
18. Mixed hepatocellular-cholangiocarcinoma may derive from "hepatogones".
Hunt JP; Varnholt H
Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):105; author reply 105-6. PubMed ID: 18234649
[No Abstract] [Full Text] [Related]
19. Clinicopathological significance of 'subtypes with stem-cell feature' in combined hepatocellular-cholangiocarcinoma.
Sasaki M; Sato H; Kakuda Y; Sato Y; Choi JH; Nakanuma Y
Liver Int; 2015 Mar; 35(3):1024-35. PubMed ID: 24712771
[TBL] [Abstract][Full Text] [Related]
20. Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X; Zhang BH; Qiu SJ; Ren ZG; Zhou J; Chen XH; Zhou Y; Fan J
Ann Surg Oncol; 2012 Sep; 19(9):2869-76. PubMed ID: 22451237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
